Testing Efficacy Or Toxicity Of A Compound Or Composition (e.g., Drug, Vaccine, Etc.) Patents (Class 424/9.2)
-
Publication number: 20140378944Abstract: Methods and devices for delivering an agent to a solid tissue in vivo for assessment of efficacy are described. One method involves withdrawing of a needle from and injecting of the agent into the solid tissue; another method involves delivering the agent using a plurality of microdialysis probes to a solid tissue.Type: ApplicationFiled: July 10, 2014Publication date: December 25, 2014Inventors: Jason Frazier, Richard Klinghoffer, Marc Grenley
-
Publication number: 20140369934Abstract: The invention provides methods of identifying metakaryotic stem cells, as well as methods of identifying agents that selectively modulate the growth, migration, replication, and/or survival of these cells by detecting an intermediate dsRNA/DNA duplex genome. Also provided are diagnostic, prognostic, and treatment methods for disorders, such as atherosclerosis, restenosis, and benign or malignant tumors.Type: ApplicationFiled: June 1, 2012Publication date: December 18, 2014Inventors: William G. Thilly, Elena V. Gostjeva, B. David Stollar
-
Publication number: 20140364449Abstract: The invention relates to a method for identifying compounds that bind and preferably activate a target opioid receptor in a pH-dependent manner.Type: ApplicationFiled: January 7, 2013Publication date: December 11, 2014Applicant: MATHPHARM GMBHInventors: Christoph Stein, Marcus Weber, Olga Scharkol, Peter Deuflhard
-
Publication number: 20140363380Abstract: MEX3C deficiency impairs the development of white and brown adipose tissue. Hence the present invention provides, among other things, a method of screening a candidate compound for activity in inhibiting fat deposition in a subject in need thereof and/or treating a condition in a subject in need thereof, comprising: (a) contacting a candidate compound to a cell that expresses MEX3C protein; and then (b) detecting a quantity of expression of the MEX3C protein in the cell; a depression in the expression of MEX3C protein when the candidate compound is contacted thereto as compared to that expressed when the candidate compound is not contacted thereto indicating the compound is active in inhibiting fat deposition and/or treating a condition in a subject in need thereof. Methods of treatment and screening subjects are also described.Type: ApplicationFiled: March 14, 2014Publication date: December 11, 2014Applicant: Wake Forest University Health SciencesInventors: Baisong Lu, Colin E. Bishop
-
Patent number: 8906389Abstract: The invention relates to methods and reagents for determining efficacy of vaccine, particularly of a tuberculosis vaccine.Type: GrantFiled: December 21, 2011Date of Patent: December 9, 2014Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbHInventors: Christiane Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
-
Publication number: 20140356290Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.Type: ApplicationFiled: June 6, 2014Publication date: December 4, 2014Inventors: Neil Barman, Howard Levin, Paul Sobotka, Mark Gelfand
-
Publication number: 20140356291Abstract: IDH1-mutant cell lines and xenografts (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) are derived from human glioblastoma multiforme (GBM) samples. Methods use said cells and xenografts as tools for determining the impact of IDH1R132H on cancer properties including cellular morphology, tumorigenesis, DNA, apoptosis, and metabolic profiles. Methods also use these cell lines for the screening and identification of candidate therapeutic targets.Type: ApplicationFiled: December 10, 2012Publication date: December 4, 2014Applicant: DUKE UNIVERSITYInventors: Hai Yan, Darell D. Bigner
-
Publication number: 20140356292Abstract: A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis drugs and atypical anti-psychosis drugs is found. An in vivo animal model for screening of a therapeutic agent for improving cognitive dysfunction by schizophrenia is provided.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventor: Takeo ISHIYAMA
-
Patent number: 8901276Abstract: The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.Type: GrantFiled: December 19, 2011Date of Patent: December 2, 2014Assignee: The Regents of the University of MichiganInventors: Thomas D. Wang, Sharon Miller, Bishnu Joshi
-
Publication number: 20140348749Abstract: In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to glucose restriction are provided. In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to OXPHOS inhibitors are provided. In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to biguanides are provided. In some aspects, methods of identifying subjects with cancer who are candidates for treatment with an OXPHOS inhibitor are provided. In some aspects, methods of identifying subjects with cancer who are candidates for treatment with a biguanide are provided. In some aspects, methods of treating subjects with cancers that are sensitive to glucose restriction are provided.Type: ApplicationFiled: February 25, 2014Publication date: November 27, 2014Applicant: Whitehead Institute for Biomedical ResearchInventors: Kivanc Birsoy, Richard Possemato, David M. Sabatini
-
Publication number: 20140348751Abstract: A method for testing, treating, and preventing delayed food allergies includes: receiving detailed symptom, medical, and dietary histories from a patient; formulating a combination of one or more food extracts at selected concentrations for sublingual administration over a trial period; determining whether the patient's symptoms have improved, worsened, or had no change, in response to the administration of the combination; and altering the combination in response to whether the patient's symptoms have improved, worsened, or not changed, so as to induce immune system food tolerance.Type: ApplicationFiled: August 12, 2014Publication date: November 27, 2014Inventor: John Shea
-
Publication number: 20140348750Abstract: Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.Type: ApplicationFiled: December 10, 2012Publication date: November 27, 2014Inventors: Robert Vince, Swati Sudhakar More
-
Patent number: 8894974Abstract: A method for treating a human patient is provided, including administering a radiolabeled form of a therapeutic agent to the patient at a first substantially non-therapeutically-effective dose, wherein pharmacological activity of the therapeutic agent is not due to radioactivity of the therapeutic agent. The method also includes determining information related to a biodistribution of the radiolabeled form of the therapeutic agent in the patient by performing a radioimaging procedure on the patient. Responsively to the information, a decision is made whether or not to treat the patient by administering the therapeutic agent to the patient. If the decision is made to treat the patient, the patient is treated by administering the therapeutic agent to the patient at a second therapeutically-effective dose. If the decision is made not to treat the patient, treatment of the patient with the therapeutic agent is withheld. Other embodiments are also described.Type: GrantFiled: May 11, 2007Date of Patent: November 25, 2014Assignee: Spectrum Dynamics LLCInventors: Benny Rousso, Chalom Bruno Sayada
-
Patent number: 8895029Abstract: The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against Leptospira borgpetersenii serovar hardjo (type hardjo-bovis) by using Leptospira interrogans serovar hardjo (type hardjoprajitno).Type: GrantFiled: January 13, 2014Date of Patent: November 25, 2014Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventor: Carol L. Rinehart
-
Patent number: 8894973Abstract: The invention is a method for the differential diagnosis of chronic schizophrenia or chronic alcoholism, by imaging the brain of a subject to detect any or all of the markers phosphocreatine (PCr), N-acetyl aspartate divided by the total creatine signal (NA/Crt), and synaptic phosphodiester (sPDE), and determining any increase or decrease in the presence of such markers compared to normal levels in specified anatomic areas of the brain. The output of such a method, resulting from such imaging, is presented to be viewed by a diagnostician in order to support the differential diagnosis based on the data output.Type: GrantFiled: August 13, 2012Date of Patent: November 25, 2014Inventors: Jay W. Pettegrew, Kanagasabai Panchalingam
-
Patent number: 8889153Abstract: A compound comprising combination of an immunomodulator and to at least one anti-pathogenic agent for treating of facultative or strict infections caused by intracellular microorganisms, the components of the combination or association of substances of the invention, the immunomodulator (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance with antimicrobial properties can be administered either jointly, simultaneously, consecutively or sequentially, in an appropriate form, according to their chemical properties, and in a dose effective against microorganisms in human and animals.Type: GrantFiled: January 27, 2009Date of Patent: November 18, 2014Inventor: Iseu da Silva Nunes
-
Publication number: 20140335023Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.Type: ApplicationFiled: July 23, 2014Publication date: November 13, 2014Applicant: Dyax Corp.Inventors: Daniel J. Sexton, Malini Viswanathan
-
Patent number: 8883425Abstract: The present invention relates to methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. The invention thus provides a method, comprising contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No: 194-309; and measuring a compound-polypeptide property related to the differentiation of said cells. The invention further relates to a bone formation enhancing pharmaceutical composition, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean bone density in a subject. Furthermore, the invention relates to a method for the in vitro production of bone tissue.Type: GrantFiled: October 30, 2012Date of Patent: November 11, 2014Assignee: Galapagos N.V.Inventors: Luc Juliaan Corina Van Rompaney, Peter Herwig Maria Tomme, Robin John Brown
-
Patent number: 8883173Abstract: The current invention relates to the diagnosis and treatment of diseases resulting from infections by Mycobacterium avium subsp. paratuberculosis. In particular the invention relates to the use of an antigen selected among (a) a synthetic peptide 5P having the following formula: DPhe-NMeVal-Ile-Phe-Ala-OMe (SEQ ID NO: 1); (b) a lipopeptide L5P consisting of the synthetic peptide a) wherein the N-terminal phenylalanine residue is N-acylated with an eicosanoic acid acyl chain; (c) a variant of peptide a) or lipopeptide b) able to react with anti-Mycobacterium paratuberculosis antibodies; for in vitro detection or quantification of specific anti-Mycobacterium paratuberculosis antibodies in a biological sample.Type: GrantFiled: October 24, 2008Date of Patent: November 11, 2014Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Institut National de la Recherche Agronomique, Institut PasteurInventors: Sylvie Bay, Franck Biet
-
Patent number: 8883123Abstract: The present invention relates to a method of reducing the transmission of a pathogen from an animal of a first species to an animal of a second species. Specifically, reduction of transmission is accomplished through the administration of antigen of the pathogen such that administration results in the reduction or absence of the reproduction of the pathogen in the animal to which the antigen was administered.Type: GrantFiled: October 27, 2006Date of Patent: November 11, 2014Assignee: Boehringer Ingleheim Vetmedica, Inc.Inventors: Juergen Daemmgen, Eric Martin Vaughn
-
Patent number: 8877483Abstract: An accelerating agent for elimination of dioxins which comprises, as an active ingredient, a microorganism having an activity of accelerating elimination of dioxins in the body to the outside of the body.Type: GrantFiled: May 30, 2003Date of Patent: November 4, 2014Assignee: Calpis Co., Ltd.Inventors: Tadashi Shinoda, Akihiro Masuyama, Hidetoshi Morita, Hiroshi Yoshikawa
-
Publication number: 20140322135Abstract: The invention provides methods for treating myelodysplastic syndrome (MDS). The invention is generally directed to reducing certain overt symptoms and disease-causing biological events in MDS by administering certain cells to a subject having MDS. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to affect these events. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for affecting these events.Type: ApplicationFiled: April 30, 2014Publication date: October 30, 2014Applicant: Katholieke Universiteit LeuvenInventors: Valerie Roobrouck, Michel Delforge, Catherine M. Verfaillie
-
Publication number: 20140322136Abstract: The present invention provides methods to reduce or inhibit weight gain by administering inhibitors of the SirT1 protein to a subject. Methods to identify such inhibitors are also disclosed.Type: ApplicationFiled: May 6, 2014Publication date: October 30, 2014Inventors: Yansong GU, Hongzhe LI
-
Patent number: 8871995Abstract: The present invention provides a method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to the report of the International Dry Eye WorkShop (DEWS Report) (2007) and a pharmaceutical composition comprising the agent. The present invention further provides a method for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to DEWS Report (2007) using the agent.Type: GrantFiled: November 26, 2010Date of Patent: October 28, 2014Assignee: R-Tech Ueno, Ltd.Inventors: Yukihiko Mashima, Akio Siranita
-
Publication number: 20140314675Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.Type: ApplicationFiled: September 7, 2012Publication date: October 23, 2014Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20140314674Abstract: Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.Type: ApplicationFiled: April 16, 2014Publication date: October 23, 2014Applicant: Signal Pharmaceuticals, LLCInventors: HEATHER RAYMON, KRISTEN MAE HEGE
-
Publication number: 20140308209Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: November 15, 2012Publication date: October 16, 2014Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Patent number: 8858938Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: September 13, 2013Date of Patent: October 14, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation of the Advancement of Military Medicine, Inc.Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
-
Patent number: 8858915Abstract: The object is to provide: a therapeutic or prophylactic agent for metabolic syndrome, which has improved stability in a living body; and others. The therapeutic or prophylactic agent for metabolic syndrome comprises, as an active ingredient, DNA that encodes receptor activity-modifying protein (RAMP) 2 and is selected from the items (a) to (d) below or a polypeptide encoded by the DNA: (a) DNA which has the nucleotide sequence depicted in SEQ ID NO:1; (b) DNA which has a nucleotide sequence capable of hybridizing with the nucleotide sequence depicted in SEQ ID NO:1 under stringent conditions; (c) DNA which has a nucleotide sequence encoding an amino acid sequence having the substitution, deletion and/or addition of one or more amino acid residues in the amino acid sequence depicted in SEQ ID NO:2; and (d) DNA which has a nucleotide sequence having a 90% or more homology with the nucleotide sequence depicted in SEQ ID NO:1.Type: GrantFiled: November 21, 2008Date of Patent: October 14, 2014Assignee: Japan Science & Technology AgencyInventor: Takayuki Shindo
-
Publication number: 20140301949Abstract: The present invention relates to methods and systems for resuscitation of an infant which maintains healthy blood oxygen saturation values in the infant by titration of supplemental oxygen concentrations.Type: ApplicationFiled: April 8, 2014Publication date: October 9, 2014Applicant: UTI Limited PartnershipInventor: Yacov RABI
-
Publication number: 20140303481Abstract: Methods and systems are described for quantitatively determining a score for a patient having a disorder, e.g. a stroke, in a tissue, such as the brain, by analyzing both the extent and location of damage to the tissue caused by the disorder.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Gregory Sorensen, Nina M. Menezes, Hakan Ay
-
Patent number: 8852556Abstract: A method for evaluating the effect of a compound on vasomotor response in vivo comprises the steps of administering said compound to a rabbit and measuring the diameter of the vessel lumen of a central ear artery of said rabbit in comparison with the baseline diameter of the vessel lumen of said central ear artery of said rabbit, said baseline diameter being measured prior to the administration of said compound.Type: GrantFiled: October 21, 2009Date of Patent: October 7, 2014Assignee: Janssen Research & Development LLCInventors: Tom Jay Parry, Bruce P. Damiano, Edward C. Giardino, Margery A. Connelly
-
Publication number: 20140294731Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).Type: ApplicationFiled: October 5, 2012Publication date: October 2, 2014Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
-
Publication number: 20140294728Abstract: Methods and systems for detecting efforts to thwart the sense of smell of service animals and sniffer dogs. Methods and systems for detecting the introduction of and for neutralizing the effects of ONM introduced into an area. Methods and systems for the controlling the direction of the emission or ONM or descanter into an area. This abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure and is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims, 37 C.F.R. 1.72(b).Type: ApplicationFiled: April 1, 2013Publication date: October 2, 2014Inventor: Guy L. McClung, III
-
Publication number: 20140294730Abstract: The present invention provides compositions and methods useful for diagnosing, monitoring the progression, identifying the location, and monitoring the treatment response in ovarian cancer based on detecting and locating VCAM-1 expression.Type: ApplicationFiled: March 28, 2014Publication date: October 2, 2014Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Jill K. Slack-Davis, Kimberly A. Kelly
-
Publication number: 20140298497Abstract: The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest.Type: ApplicationFiled: November 2, 2012Publication date: October 2, 2014Inventors: Michel Arock, Peter Valent, Rosine Saleh, Ghaith Wedeh, Christian Auclair
-
Publication number: 20140294732Abstract: The present application provides a method for diagnosing a neurodegenerative disease in a subject at risk of having said neurodegenerative disease, said method comprising the steps of a) having said subject at risk of having said neurodegenerative disease perform a series of fast, brief and powerful movements that recruit fast-fatigable motoneurons (ballistic movements), and b) comparing the performance in step a) of said subject at risk of having said neurodegenerative disease with a standard value obtained by assessing the performance of a normal population for the same series of fast, brief and powerful movements that recruit fast-fatigable motoneurons, wherein a significant deviation of performance by said subject at risk of having said neurodegenerative disease is indicative of the onset of said neurodegenerative disease.Type: ApplicationFiled: November 7, 2012Publication date: October 2, 2014Inventors: Pico Caroni, Francesco Roselli
-
Publication number: 20140294729Abstract: The invention relates to methods for identifying compounds and compositions that target cancer stem cells. In some aspects, the invention relates to treatment methods that use compounds and compositions that specifically target cancer stem cells for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof. Other aspects of the invention relate to the use of cancer stem cell biomarkers in the selection of a treatment for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof.Type: ApplicationFiled: October 28, 2013Publication date: October 2, 2014Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: PIYUSH GUPTA, TAMER T. ONDER, ERIC S. LANDER, ROBERT A. WEINBERG, SENDURAI MANI, MAI-JING LIOA
-
Patent number: 8847003Abstract: The invention provides methods of preventing or treating drug addiction, or ameliorating the craving for an addictive drug, as well as compounds, peptides, and pharmaceutical compositions that may be used to prevent or treat drug addiction or ameliorate the craving for an addictive drug. The invention also provides methods for identifying agents that may be used to prevent or treat drug addiction, or ameliorate the craving for an addictive drug.Type: GrantFiled: January 11, 2012Date of Patent: September 30, 2014Inventor: Pietro P. Sanna
-
Publication number: 20140286868Abstract: Immortalized human cell lines derived from prostate cells are disclosed. Immortalized cells derived from a human epithelial prostate tissue cancer tumor are provided, as well as immortalized cells derived from healthy human epithelial prostate tissue from the same patient. Methods for utilizing such immortalized cell lines for researching, screening, and evaluating antimalignancy therapies and drug candidates are also disclosed.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Applicant: TUSKEGEE UNIVERSITYInventors: Clayton Yates, Timothy Turner
-
Publication number: 20140286867Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: ApplicationFiled: April 30, 2014Publication date: September 25, 2014Inventors: Rebecca S. Hoffman, Mark Weinberg
-
Publication number: 20140286870Abstract: The present invention relates to a method and composition for the aspiration, processing, testing and infusion of bone marrow derived stem cells, as an adjuvant treatment in cardiovascular disorders. More specifically, the invention provides for the methods and compositions for the aspiration, analysis, processing, infusate preparation and infusion of bone-marrow derived stem cells, particularly in a rapid point-of-care environment, wherein a centrifugal fractionation and optically monitored separation of the bone marrow yield desired cellular product in the desired concentration and viscosity.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventors: Kenneth Harris, Dalip Sethi, Venkatesh Ponemone, Gary R. Cohan
-
Publication number: 20140286869Abstract: The present invention relates to a method and composition for the aspiration, processing, testing and infusion of bone marrow derived stem cells, as an adjuvant treatment in cardiovascular disorders. More specifically, the invention provides for the methods and compositions for the aspiration, analysis, processing, infusate preparation and infusion of bone-marrow derived stem cells, particularly in a rapid point-of-care environment, wherein a centrifugal fractionation and optically monitored separation of the bone marrow yield desired cellular product in the desired concentration and viscosity.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventors: Kenneth Harris, Dalip Sethi, Venkatesh Ponemone, Gary R. Cohan
-
Publication number: 20140286871Abstract: The subject technology relates generally to compositions and methods for producing plasmid DNA of a desired quality. In addition, it relates to the discovery of Escherichia coli (E. coli) bacteria with a constitutive methylase gene stably incorporated into the chromosomal DNA and uses thereof.Type: ApplicationFiled: September 21, 2012Publication date: September 25, 2014Inventor: Alan P. Escher
-
Publication number: 20140271479Abstract: The present disclosure provides a method of inducing or modulating reward- or aversive-related behaviors in animals using light-responsive opsins. The present disclosure provides methods of identifying or screening compounds that may be used to treating mental disorders, or are relevant to disrupt or improve reward- or aversive related behaviors.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Stephan Lammel, ByungKook Lim, Robert C. Malenka
-
Publication number: 20140271480Abstract: The present invention provides a method of using indole-ketone or indolidone to treat or prevent a neurodegenerative disease or disorder. In one embodiment, the neurodegenerative disease is Parkinson's disease. In another embodiment, the neurodegenerative disease or disorder is associated with excessive neuronal Nitric Oxide Synthase (nNOS) activity. Examples of indole-ketone include, but are not limited to, SU4312, SU5416, SU11248 (Sunitinib), and indirubin-3-oxime.Type: ApplicationFiled: October 25, 2012Publication date: September 18, 2014Inventors: Ming Yuen Lee, Yifan Han, Chung Lit Choi, Zaijun Zhang, Wei Cui
-
Patent number: 8834843Abstract: The present invention relates to a method useful in facilitating the identification of fibrogenesis in a subject. The method of the invention is particularly useful when applied as part of a method to diagnose fibrogenesis of the liver. The invention also provides a compound for use in a method for identification of fibrogenesis in a subject A further aspect of the invention is a compound for use in the preparation of a medicament for use in a method for identification of fibrogenesis in a subject.Type: GrantFiled: November 19, 2008Date of Patent: September 16, 2014Assignee: GE Healthcare LimitedInventors: Ben Newton, Salah Chettibi, Magne Solbakken
-
Publication number: 20140255310Abstract: The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.Type: ApplicationFiled: February 13, 2014Publication date: September 11, 2014Applicant: ARENA PHARMACEUTICALS, INC.Inventors: Yaron Hakak, David J. Unett, Joel Gatlin, Chen W. Liaw
-
Patent number: 8828356Abstract: Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression.Type: GrantFiled: April 4, 2013Date of Patent: September 9, 2014Assignees: Progeria Research Foundation, Inc., The United States of America as represented by the Secretary of the Department of Health and Human Services, The University of North Carolina at Chapel Hill, The Regents of the University of MichiganInventors: Leslie B. Gordon, Francis S. Collins, Thomas Glover, Michael W. Glynn, Brian C. Capell, Adrienne D. Cox, Channing J. Der
-
Patent number: 8828671Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.Type: GrantFiled: February 5, 2013Date of Patent: September 9, 2014Assignee: Laboratory Corporation of America HoldingsInventors: Norman B. Purvis, Gregory T. Stelzer